Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2399221 | 0.91 | ADRA2A (0.43) | ADRA1AIDO1SIGMAR1CHRNA7ADRA2A | |
| SCHEMBL7498131 | 0.77 | PRCP (0.51) | — | |
| SCHEMBL458139 | 0.73 | — | — | |
| SCHEMBL4955252 | 0.73 | MTNR1A (0.33) | — | |
| SCHEMBL5680358 | 0.72 | ADRA1A (0.39) | ADRA1AIDO1PDPK1SIGMAR1CYP11B2 | |
| SCHEMBL18249682 | 0.72 | ADRA1A (0.37) | ADRA1AIDO1PDPK1SIGMAR1CYP11B2 | |
| SCHEMBL4795332 | 0.71 | ADRA1A (0.44) | ADRA1AIDO1PDPK1SIGMAR1CYP11B2 | |
| SCHEMBL4721678 | 0.70 | ALDH1A1 (0.30) | — | |
| SCHEMBL4721538 | 0.70 | CYP1B1 (0.32) | — | |
| SCHEMBL18554493 | 0.70 | CYP1A2 (0.43) | ADRA1AIDO1PDPK1CYP11B2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129333-A1 | 1-Thia-2,4a-diaza-cyclopenta[b]naphthalene-3,4-diones and related compounds as anti-infective agents | ACHILLION PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | claimed |
| WO-2006074317-A1 | 1-THIA-2,4A-DIAZA-CYCLOPENTA[B]NAPHTHALENE-3,4-DIONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS | ACHILLION PHARMACEUTICALS, INC. (US) | 2006-07-13 | — | — | WO | claimed |
| EP-2576561-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120309773-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. | 2012-12-06 | — | — | US | disclosed |
| EP-2516444-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-10-31 | — | — | EP | disclosed |
| WO-2012106448-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | WO | disclosed |
| EP-2470537-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011150356-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2324020-A2 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2011031554-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| US-7659399-B2 | 1-thia-2,4a-diaza-cyclopenta[b]napththalene-3,4-diones and related compounds as anti-infective agents | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-02-09 | — | — | US | disclosed |
| WO-2010014930-A2 | THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20070129333-A1 | 1-Thia-2,4a-diaza-cyclopenta[b]naphthalene-3,4-diones and related compounds as anti-infective agents | ACHILLION PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| WO-2006074317-A1 | 1-THIA-2,4A-DIAZA-CYCLOPENTA[B]NAPHTHALENE-3,4-DIONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS | ACHILLION PHARMACEUTICALS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| US-6794380-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE; ANTIALLERGENS | ASTRAZENECA AB (SE) | 2004-09-21 | — | — | US | disclosed |
| US-20030186966-A1 | Amide derivatives | ASTRAZENECA AB | 2003-10-02 | — | — | US | disclosed |
| WO-1994020096-A1 | METHOD OF EMPLOYING CARBAZOLYL-(4)-OXYPROPANOLAMINE COMPOUNDS FOR INHIBITION OF SMOOTH MUSCLE CELL PROLIFERATION | BOEHRINGER MANNHEIM PHARMACEUTICALS CORPORATION - SMITHKLINE BECKMAN CORPORATION LIMITED (US) | 1994-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | ADRA1A 4237/4885IDO1 91/4885PDPK1 443/4885 |
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | ADRA1A 4736/4885IDO1 420/4885PDPK1 258/4885 |
| US-20030186966-A1 | Amide derivatives | IL6, IL6ST, IFNG | ADRA1A 706/4885IDO1 451/4885PDPK1 4879/4885 |
| US-20120309773-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | JAK2, JAK1, JAK3 | ADRA1A 4737/4885IDO1 439/4885PDPK1 257/4885 |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | ADRA1A 4637/4885IDO1 365/4885PDPK1 242/4885 |
| US-20070129333-A1 | 1-Thia-2,4a-diaza-cyclopenta[b]naphthalene-3,4-diones and related compounds as anti-infective agents | CCNA1, TOP1, DNA2 | ADRA1A 238/4885IDO1 204/4885PDPK1 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.